You are here

Home » Content

Göz tutulumlu Behçet hastalığında siklosporin-A ve bromokriptin kombine tedavisinin görsel sonuçları

Visual results of combined cyclosporine-A and bromocriptine treatment in ocular Behçet' s disease

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1994

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The effects of combined low-dose cyclosporine-A (4 mg kg day) and bromocriptine (".5 mg day) treatment on visual acuity and frequency of ocular attacks were studied in 13 ocular Behçet patients. Duration of treatment was between 5 and 25 months. There was a significant (p< 0.05) decrease in frequency of ocular attacks- in almost all the patients compared to periods of treatment with other drugs. Initial visual acuity was preserved or became better in 76.9 % of patients. However, a decrease in visual acuity was observed in 23.0 %. The difference in increased visual acuity between convantional and combined therapy groups was not significant (p>0.05). Increase in creatinin level was observed only in one patient and treatment was discontinued, (iingival hyperplasia (3 patients), hirsutism (3 female patients), decrease in libido (2 male patients), fine tremor of hands (1 patient), parestesia (2 patients) and headache (2 patients) were observed during treatment. Neuro-Behçet symptoms appeared in two patients. [Journal of Turgut Özal Medical Center 1(2): 112-116 ,1994
Bookmark/Search this post with
Abstract (Original Language): 
Onüç oküler Behçet Hastasında ortalama 13.3 (5-25) aylık düşük doz siklosporin-A (4 mg kg gün) ve bromokriptin (" 5 mggün) kombine tedavisinin görme keskinliği ve oküler atak sayısına etkinliği incelendi. Hastaların hemen hepsinde, diğer ilaçlarla tedavi oldukları doneme kıyasla oküler atak sayısında anlamlı derecede (p<0.05) azalma oldu. Hastaların % ~6.9' unda başlangıç görmenin korunduğu ya da daha iyiye gittiği ancak % 23.0' ında görme azalması olduğu gözlendi. Ancak görme keskinlikleri farkı anlamlı değildi (p>0.05). Sadece bir hastada kreatinin yükseldi ve tedavisi kesildi. 3 hastada gingival hiperplazi. 3 bayan hastada hirsutizm, 2 erkek hastada libido azalması, 1 hastada ince el tremoru, 2 hastada parestezi ve 2 hastada başağrısı gözlendi. 2 hastada Nöro-Behçet bulguları ortaya çıktı, diğer bir hastada da mevcut \öro-Behçet klinik tablosunda artma oldu. [Turgut Özal Tıp Merkezi Dergisi 1(2): 112-116.1994}
FULL TEXT (PDF): 
PDF icon arastirmax-goz-tutulumlu-behcet-hastaliginda-siklosporin-bromokriptin-kombine-tedavisinin-gorsel-sonuclari.pdf
  • 2
112-116
  • Turkish

REFERENCES

References: 

1. Kanski JJ. Clinical Ophthalmology. Toronto. Butter Worths and Co Ltd. 1989.
2.
Özdemi
r Ö. Behçet hastalığının klinik belirtileri. Turaçlı ME (ed): Üvea iltihapları ve Behçet hastalığı (V. Ulusal Oftalmoloji Kursu). Ankara: Öztek matbacılık, 1985: 37-42.
3. Nussenblatt RB, Palestine AG, Chan C. Effectiveness of cyclosporin therapy for Behçet's
Hepşen ve ark.
(JÖZ tutulumlu Behçet hastalığında siklosporin-A ve bromokriptin kombine tedavisinin görsel sonuçları
disease. Arthritis and Reunıatism 1985; 28: 671-9.
4. Bonnet
M
. Behçet Sendromunun tedavisinde immundepressörler. Turaçlı ME (ed): Üvea İltihaplan ve Behçet Hastalığı (V. Ulusal Oftalmoloji Kursu). Ankara. Öztek Matbacılık, 1985: 65-72.
5. Masuda K, Urayama A, Kogure M. Double-masked trial of cyclosporin versus colchicine and long-term open study öf cyclosporin in Behçet's disease. The Lancet Saturday 1989; 20: 1093-5.
6.
Özyazga
n Y, Yurdakul S, Aktunç T. Behçet Hastalığı ile birlikte seyreden üveitlerin tedavisinde düşük doz siklosporin-A ile siklofosfamidin tek kör kullanılması. TOD XXIV. Ulusal Kongresi Bülteni. Ankara. Yıldırım Basımevi. 1990: 107.
7. Davidson C, Green WR, Wong VG. Retinal atrophy induced by intravitreous colchicine. Invest Ophthalmol Vis Sci 1983; 24: 301-11.
8. Nussenblatt RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 1986; 31: 159-69.
9. Yazıcı H, Pazarlı H, Barnes CG. A controlled trial of azathioprine in Behçet's Syndrome. The New Eng J Med 1989; 322: 1725-38.
10. Ben Ezra D, Choen E, Chajek T. Evaluation of convantional therapy versus cyclosporin-A in Behçet's Sydrome. Transplantation Proceedings 1988; 20: 136-43.
11. Busch R, Ruzicka T, Donhauser G. Cyclosporin-A Therapie des Morbus Behçet. Hautarzt 1990; 41: 229-31.
12. Livoshi E, Takahashi Y, Sasaki T. Treatment of skin symptoms of Behçet's disease with low dose cyclosporin-A. Nippon Hifuka Gakkai Zasshi 1990; 99: 877-81.
13. Diaz-Liopis M, Cervera M, Menezo JL Cyclosporin-A treatment of Behçet's disease: a long-term study. Curr Eye Res 1990; 9: 17-23.
14.
Aktun
ç T, Bahçecioğlu H, Dikici K Behçet Hastalığında kombine immunsupressif tedavinin erken sonuçları. TOD XXIV. Ulusal Kongresi Bülteni. Ankara: Yıldırım Basımevi. 1990: 121-3
15. Blank M, Palestine AG, Nussenblatt RB Down-regulation of autoantibody levels of cyclosporine and bromocriptine treatment in patient with uveitis. Clin Immunol Immunopathol 1986; 54: 87-97.
16. Palestine AG, Nussanblatt RB, Gelato M Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine Transplantation Proceedings 1988; 20: 131-5.
17. Kolodziej-Maciejewska H, Reterski Z. Positive effect of bromocriptine treatment in Graves disease orbitopaty. Exp Clin Endocrinol 1985; 86: 241
18. Palestine AG, Meullenberg-Coulombre CG, Kim MK. Bromocriptine and low-dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat. J Clin Invest 1987; 79: 1078-81.
19. Kalian BD. Cyclosporine. The New England J Med 1989; 321: 1725-38.
20. Mochizuki M, Masuda K, Sakane T, Ito K, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993; 115: 763-69.

Thank you for copying data from http://www.arastirmax.com